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Laila Adel Al Dehailan 
 
INVESTIGATIONS OF THE ANTI-CARIES POTENTIAL OF FLUORIDE 
VARNISHES 
The majority of currently marketed fluoride varnishes (FV) have not been 
evaluated for their effectiveness in preventing dental caries. Fundamental research on 
FVs and how different formulations affect adherence to teeth, fluoride release into saliva 
and uptake by teeth is virtually non-existent. The objective of this work was to 
investigate the anti-caries potential, measured as fluoride release into saliva, change in 
surface microhardness of early enamel caries lesions, and enamel fluoride uptake, 
of multiple commercially available FVs. We have found that FVs differed in their release 
characteristics, rehardening capability, and ability to deliver fluoride to demineralized 
lesions. In addition to our in vitro work, we have conducted a clinical study that aimed to 
compare saliva and plaque fluid fluoride concentrations following the application of three 
commercially available FV treatments at predetermined post application time points. We 
also investigated the change in fluoride concentration in saliva and plaque fluid fluoride 
from baseline to each post application predetermined time point. We found that FVs 
varied in their release of fluoride into saliva and plaque fluid but shared common trends 
in release characteristics. The outcomes of our in vitro and in vivo investigations 
demonstrate a great variation in anti-caries potential of FVs. This may be attributed 
to different compositions and physical properties of the tested FVs. 
       E. A. Martinez-Mier, D.D.S., Ph.D., Chair  
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INTRODUCTION 
 2 
Dental Caries and Fluoride Varnishes 
Dental caries remains the most common chronic disease globally, affecting 60-
90% of school-aged children and a significant number of adults.1 Topically applied 
fluoride has contributed to major reductions in both the incidence and prevalence of 
dental caries. It has also been shown to be safe and effective.2 Fluoride has the ability to 
inhibit the demineralization process, enhance remineralization, and inhibit bacterial 
enzymes found in dental plaque.3, 4 Nowadays, a vast range of professionally applied 
topical fluoride products exists, including rinses, gels, foams, drops, and varnishes. 
Fluoride varnishes (FV) are relatively simplistic delivery vehicles for cariostatic amounts 
of fluoride and typically contain 5% sodium fluoride. FV offers several advantages over 
other modalities of topical fluoride treatment such as effectiveness, relative safety and 
ease of application.5, 6 The prolonged contact time with the dentition and extended release 
of fluoride over a longer period of time compared to other topical vehicles gives FV an 
advantage over other forms of fluoride delivery.7-10 
Current Regulations and Recommendations 
In 1994, the US Food and Drug Administration approved fluoride varnishes  
  as cavity liners and dentin hypersensitivity treatments. However, most dental 
professionals in the US use fluoride varnishes off-label for the prevention of dental 
caries.7, 10  
Despite the American Dental Association Council on Scientific Affairs’ evidence-
based clinical recommendation for people at risk of developing dental caries that “FV 
containing 2.26 percent fluoride applied at least twice per year is effective in preventing 
caries for patients 6 years or older”, the current regulatory situation has created a ‘grey 
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area’ for manufacturers (a recent search brought more than 30 different manufacturers to 
daylight).11 Thus, unlike for fluoride dentifrices and rinses, no efficacy testing is required 
for FV, or in other words – the majority of currently marketed FV have not been 
evaluated for their effectiveness in preventing caries or their toxicity.10 Considering the 
importance of a professional caries intervention and the fact that FV are typically only 
applied every 3-6 months, every effort should be taken to ensure a maximum benefit to 
risk ratio. 
Relevance of Existing Research 
Several recent studies highlighted considerable differences in fluoride release 
characteristics between FVs from different manufacturers, not only in terms of 
cumulative amount of fluoride released over time, but also in the kinetics of fluoride 
release.7, 12 The clinical relevance of these findings is unknown due to the lack of 
comparable FV clinical trials on caries progression and reversal. Fundamental research 
on FV and how different formulations affect adherence to teeth, fluoride release into 
saliva and uptake by teeth – to name their most important aspects - is virtually non-
existent. Thus, further research is required first to establish a baseline before 
experimental work can commence. 
In Vitro Models and Outcome Variables 
pH cycling models were designed to simulate the dynamic variations in mineral 
saturation and pH associated with the natural caries process. They mimic specific events 
of the caries process under controlled conditions and allow the investigation of individual 
mechanistic variables which would be extremely difficult to do under in vivo 
conditions.13 At the same time, it is important to recognize the limitations of in vitro 
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experiments in their ability to reproduce the whole complexity of caries dynamics. In 
vitro experiments provide only limited information on the effects of different variables on 
the caries process. This must be taken into consideration when in vitro data are 
extrapolated to in vivo conditions. 
Many response variables can be used to investigate the efficacy of fluoride 
treatments. One of these is hardness measurement, which can quantitatively describe the 
depth of artificial lesions.14 Hardness measurement has been proven to have adequate 
sensitivity to detect early changes in the outer layer of enamel.15, 16 However, this 
technique has its limitations. The size of the indentation is highly influenced by water and 
organic content of tissue. This has a bigger impact when analyzing dentin and may affect 
the analysis of results.17 Also, hardness measurement is unable to give a clear explanation 
on changes that occur deep within a carious lesion.18 
Fluoride uptake is a widely used assessment tool to determine the amount of 
fluoride that has been incorporated in enamel lesions following fluoride treatment.18 It is 
considered as an important research method for testing new formulations for their anti-
caries activity. Reduction in dental caries, increased levels of remineralization and 
elevated resistance to acid challenge, has been linked to increased incorporation of 
fluoride into enamel, however it is still unclear how enamel fluoride uptake (EFU) 
correlates with anti-caries activity.19-23 One way to assess enamel fluoride uptake is by 
using the acid etch technique which has demonstrated excellent precision and accuracy.24, 
25  
The mode of action of FV is not fully understood; however, the bioavailability of 
fluoride in the oral cavity has been proven to be essential in caries prevention. Low levels 
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of fluoride over prolonged periods of time have been shown to be effective in preventing 
demineralization and enhancing remineralization.26, 27 Measuring the levels of fluoride 
over time in dental biofilms (plaque, plaque fluid and saliva) is one way to demonstrate 
its bioavailability and consequently its effect on caries activity. This method has been 
used as a research tool to investigate the anti-caries efficacy of several fluoride 
treatments.7, 28, 29 
Clinical Investigations on Fluoride Release Kinetics 
Current anti-caries models emphasize on the significance of maintaining 
cariostatic levels of fluoride in oral fluids, namely saliva and dental plaque.30 Therefore, 
studying fluoride concentration changes in saliva and dental plaque following the 
administration of topical fluoride is one way to determine efficacy as it can be indicative 
of the of fluoride levels in the aqueous phase available for interaction with the tooth 
structure.31 
Very few studies on the kinetics of fluoride in saliva following the topical 
application of FV have been reported. A study by (Twetman et al., 1999) showed that 
fluoride levels in saliva are significantly elevated following the application of FV. They 
also found that fluoride levels in saliva returned to baseline within 6 h for any of the 
tested FV. The results of their study suggest a correlation between the concentration of 
fluoride in FV and the fluoride levels in saliva following the application of varnish. 32 
Only one published study investigated fluoride concentration in plaque after 
topical application of FVs in adolescents at 3 days, 7 days and 30 days post treatment. 
The study investigated FVs with varying concentrations of fluoride. They found an 
elevation in fluoride concentration in plaque fluid following the application of FVs that 
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lasted for up to one week. Some FVs demonstrated an increase in fluoride levels in 
plaque that lasted for 30 days. Their work suggested different patterns of fluoride 
retention for different varnishes that is time and dose dependant.33  
The use of FV as an effective caries prevention modality is widely accepted. 
However, there is no evidence as to which in vitro parameters are more relevant in 
predicting clinical efficacy of FV. Furthermore, there is lack in clinical studies that 
investigate the efficacy and fluoride release kinetics of different formulations. Therefore, 
the overall aim of this project was to characterize FVs based on in vitro outcome 
variables that may predict FVs anti-caries efficacy and to clinically study the kinetics of 
fluoride release into saliva and dental plaque from different FVs selected based on the 
results of the initial in vitro investigations. 
Specific Aims 
Specific Aim 1: To investigate the potential anti-caries effect of five 
commercially available FVs on artificially created early caries lesions through the 
following outcome variables: a) fluoride 6 h release into artificial saliva; b) 
microhardness; and, c) enamel fluoride uptake, after pH cycling for 5 days. . 
Specific Aim 2: To investigate the potential anti-caries effect of fourteen 
commercially available FVs on artificially created early caries lesions through the 
following outcome variables: a) fluoride 24 h release into artificial saliva; b) 
microhardness; and, c) enamel fluoride uptake, after pH cycling for five-day with a 
second demineralization challenge. 
Specific Aim 3: To investigate fluoride levels in saliva and plaque fluid of 
children aged seven to eleven years after the topical application of three commercially 
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available FVs selected based on the results of the two previous laboratory investigations. 
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CHAPTER ONE: THE EFFECT OF FLUORIDE VARNISHES ON CARIES 
LESIONS 
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MATERIALS AND METHODS 
Specimen Preparation 
Enamel specimens obtained from bovine teeth were used as the hard tissue test 
substrate. The teeth were cut into 4 × 4 mm specimens using a Buehler Isomet low-speed 
saw. The teeth were stored in deionized water saturated with thymol during the sample 
preparation process. The 4 × 4 mm specimens were ground and polished to create flat 
surfaces to facilitate surface microhardness testing using Struers Rotopol 31/Rotoforce 4 
polishing unit (Struers Inc., Cleveland, PA, USA). The dentin and enamel sides of the 
specimens were ground flat to a uniform thickness with 500-grit silicon carbide grinding 
paper. As a final cleaning step, the specimens were sonicated in a detergent solution 
(Micro-90 concentrated cleaning solution with 2% dilution) for 3 min. The specimens 
were finally assessed under Nikon SMZ 1500 stereomicroscope at 10× magnification. 
Accepted specimens had no obvious cracks, areas of hypomineralization or other 
flaws in the enamel surface. Specimens were then embedded in acrylic resin (ClaroCit 
Kit, Struers) using a 1.5 inch mounting mold (Struers FlexiForm). Specimens were 
arranged to ensure they were not in contact with each other and with the enamel surface 
facing downwards. The resin was poured carefully over the specimens to a height of 
approximately 1 to 2 cm. Once the resin had cured, the specimens embedded in the disc 
(18 specimens per disc) were polished to mirror flatness as described above with a final 
polishing step using 4000-grit paper followed by 1 µm diamond polishing suspension. 
Eighteen specimens per FV treatment group were used for this study with a total of 90 
specimens. 
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Early Caries Lesion Creation 
The demineralization protocol is based on that by (White, 1987) and has been 
extensively studied using a variety of techniques over the years. 34, 35 Artificial lesions 
were formed in the enamel specimens of each disc by a 48 h immersion into a solution of 
0.1 M lactic acid and 0.2% Carbopol C907 which was 50% saturated with hydroxyapatite 
and adjusted to pH 5.0 (using KOH). Demineralization was performed at 37o C at a ratio 
of 10 ml of solution per specimen. The resulting lesions are early, shallow, subsurface 
lesions with an average depth of approximately 50 µm.  
Demineralization (Baseline) Microhardness 
Initial hardness of the demineralized specimens was determined using a Vickers 
microhardness indenter (M247AT Leco Corporation, St. Joseph, MI, USA) at a load of 
200 g for 15 s. The average specimen surface microhardness (VHNlesion) was determined 
from four indentations on the surface of each specimen. 
Fluoride Varnish Application 
A list of the tested products and their active ingredients can be found in Table 1. 
Each disc with the polished, embedded specimens was placed back into the mounting 
mold.  
The protective foil from the individual FV dose was removed and the FV mixed 
using the manufacturer’s application (typically a microbrush) for at least 10 s to 
homogenize the FV, as sedimentation of NaF and phase separation may have occurred 
during storage. Subsequently, FVs were evenly applied to the surface of each of the discs 
using the manufacturer’s applicator. The amount of FV applied was recorded. The 
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average amount applied to each treatment group consisting of 18 specimens was 0.13 g 
and ranged between 0.10 to 0.18 g.  
Saliva Incubation 
Immediately after FV application, 7.5 ml of artificial saliva (AS) that had been 
pre-heated to 37 °C was pipetted carefully over the disc in the mounting mold. The mold 
was then placed in an incubator set at 37°C. AS formulation was based on that by (Hara 
et al., 2008) and had the following composition: 2.20 g/l gastric mucin, 1.45 mM CaCl2× 
2H2O, 5.4 mM KH2PO4 , 28.4 mM NaCl, 14.9 mM KCl and was adjusted to pH 7.0 with 
KOH.36 
Every 15 min for a total of 6 h, the 7.5 ml AS were renewed by pouring the AS in 
the mold into a separate pre-weighed container to determine the weight of AS, then 
carefully pipetting fresh AS into the mold and placing the mold back into the incubator 
for another 15 min. 
These collected AS samples were then processed for fluoride analysis. An aliquot 
was removed and analyzed for fluoride using an ion-selective electrode (Model 
9609BNWP, Orion Research, Boston, MA, USA) and meter by comparison to a similarly 
prepared standard curve. Fluoride data were calculated as µg F/mg FV.  
Fluoride Varnish Removal 
After the last AS sample collection, 10 ml of chloroform was poured over the disc 
to dissolve any remaining FV. The mold was placed into a suitable container to prevent 
evaporation of the chloroform. The mold/container was gently shaken for 5 min to 
accelerate the dissolution process. This process is repeated at least once and until there 
are no visible signs of FV left on the specimens. 
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Enamel Fluoride Uptake (EFU) 
The fluoride content of the enamel in each of the discs was determined using a 
modification of the acid etch technique by Sakkab et al.37 Approximately half of the 
enamel surface of each specimen was covered with nail varnish to protect an area of the 
specimen for the subsequent pH cycling phase. Each disc was placed back into its mold. 
Specimens in each disc were acid etched by pouring 5 ml of 1M HClO4 over each disc 
for 1 min. The acid etch solution was then collected. Immediately after the etching, the 
specimens were rinsed thoroughly with deionized water. The acid etch procedure was 
repeated four more times, with each acid etch solution being collected separately. A 
sample of each acid etch solution was buffered with TISAB II (0.25 ml sample, 0.5 ml 
TISAB II and 0.25 ml 1N NaOH) and the fluoride content determined by comparison to a 
similarly prepared standard curve (1 ml standard+ 1 ml TISAB II). Data from multiple 
etches for each group were combined to calculate EFU. 
pH Cycling Phase  
Before pH cycling, the nail varnish that protected half of the specimen during 
etching for EFU was removed using acetone, and the etched half was painted with nail 
varnish. The cyclic treatment regimen for each of the five discs containing the 
demineralized specimens is provided in Table 2. Fluoride treatments were performed 
using slurries of Crest Cavity Protection (0.243 percent sodium fluoride; Procter and 
Gamble, Mason, Ohio, USA). The slurry was prepared by adding toothpaste to AS at a 
ratio of 1:2 w/w (dentifrice:AS) in a beaker with a magnetic stirrer. A fresh treatment for 
each subgroup was prepared just prior to each treatment. After the treatments, the 
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specimen discs were rinsed with running deionized water and placed back into AS. The 
remaining time (~20 h) the discs were in AS. The regimen was repeated for 5 days.  
Post Treatment Microhardness 
The average specimen microhardness was determined, as previously described, 
from four indentations on the surface of each specimen, next to the baseline indentations 
(VHNpost). The difference between the hardness after lesion creation and the pH cycling 
phase was calculated as follows: ΔVHN = VHNpost – VHNlesion 
Statistical Analysis 
Data analysis was performed using one-way analysis of variance (ANOVA). An 
overall significance of (α=0.05) was used. Pair wise comparisons between the groups was 
conducted using Student Newman Keuls test. Pearson correlation coefficients were 
calculated to investigate associations between the study variables.  
Results 
The results for all study variables can be found in Figures 1 (ΔVHN), 2 (fluoride 
release profiles), 3 (EFU) and Tables 3 (ΔVHN) and 4 (cumulative fluoride release and 
peak fluoride concentration). 
Treatment with Enamel Pro resulted in significantly greater lesion surface 
rehardening compared to all other tested FV. MI Varnish exhibited greater rehardening 
than Vanish, but was similar to PreviDent and Flor-Opal. There were no differences 
between PreviDent, Flor-Opal and Vanish. 
The fluoride release from FV showed commonalities and dissimilarities. Overall, 
fluoride release profiles were somewhat similar between FV as all showed a gradual 
decrease in released fluoride over time. However, differences were apparent in the shape 
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and slope of the release curves as well as the cumulative amount of released fluoride and 
the highest released fluoride concentration. For example, while both MI Varnish and 
Enamel Pro exhibited similar initial fluoride releases, MI Varnish released more fluoride 
than Enamel Pro during the first 3 h whereas Enamel Pro showed a more gradual 
decrease and released more fluoride during the latter 3 h of the chosen experimental 
period. Vanish released less than 1/10th of fluoride in comparison to MI Varnish and 
Vanish’ peak fluoride concentration was approximately 1/20th of that of Enamel Pro. 
The EFU data was not significantly different for all FVs tested. Enamel Pro had the 
highest EFU followed by PreviDent with both delivering more than twice as much 
fluoride compared to the other FV.  
There was no linear correlation between the main variables: ΔVHN vs. 
cumulative fluoride release (r = 0.61; p = 0.28), ΔVHN vs. EFU (r = 0.72; p = 0.17), and 
cumulative fluoride release vs. EFU (r = 0.01; p = 0.99). 
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CHAPTER TWO: AN IN-VITRO INVESTIGATION OF ANTI-CARIES 
EFFICACY OF FLUORIDE VARNISHES 
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MATERIALS AND METHODS 
Specimen Preparation 
Enamel specimens obtained from bovine teeth were used as the hard tissue test 
substrate. Selection of the tooth for processing was based on the quality of the enamel 
and whether the particular tooth surface has sufficient size to obtain a large enough 
specimen to meet the study requirements. Tooth sections with white spots, cracks and 
other defects were rejected. The tooth sections were cut into 5 × 5 mm specimens using a 
Buehler Isomet low-speed saw. The teeth were stored in deionized water saturated with 
thymol during the sample preparation process. The 5 × 5 mm specimens were ground and 
polished to create flat surfaces to facilitate surface microhardness testing using Struers 
RotoPol 31 / RotoForce 4 polishing unit (Struers Inc., Cleveland, PA, USA). The bottom 
side of the specimens was ground flat to a uniform thickness with 500-grit silicon carbide 
grinding paper. The topside of the specimens was ground using 1200-grit paper until 
most of the tooth surface is flattened. The specimens were sonicated in deionized water 
between each grinding/polishing step. As a final cleaning step, the polished specimens 
were sonicated in 2 % microliquid. The specimens were assessed with a magnification of 
10×.  
To be acceptable for the study the specimens were required to: 
a) have a minimum 5 × 5 mm  polished facet across the surface; 
b) not have any obvious cracks or other flaws in the enamel surface; 
c) have an evenly polished, high gloss enamel surface; 
d) have no contamination on the top surface from sticky wax or any other material. 
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Specimens were then secured, polished enamel side facing upwards, on a one-inch 
square acrylic block using sticky wax to facilitate surface microhardness measurements. 
When necessary, an acetone-moistened cotton swab was used to clean the polished 
enamel surface area to remove any visible debris. Then, all specimen surface areas apart 
from the polished top surface were covered with a colored nail varnish (Sally Hansen 
Advanced, Hard As Nails Nail Polish, Red, USA). Prepared specimens were stored at 
approximately 100% relative humidity and 4° C until further use. 
A total of 216 specimens were required for the present study (18 groups of 12 specimens 
each).  
Sound Enamel Microhardness 
Initial surface microhardness of the sound enamel specimens was determined 
using a Vickers microhardness indenter at a load of 200 g for 11 s (Instron T2100B 
Vickers Surface Microhardness Tester, Norwood, MA, USA). The average sound enamel 
microhardness (VHNsound) was determined from five indentations on the surface of each 
specimen. Only specimens with 300 ≤ VHNsound ≤ 400 were accepted into the study. 
Artificial Lesion Creation 
Artificial lesions were formed in the enamel specimens by a 48 h immersion at 
37° C into a solution of 0.1 M lactic acid and 0.2% Carbopol C907 which was 50% 
saturated with hydroxyapatite and adjusted to pH 5.0 using KOH. Specimens were placed 
into air-tight containers (16 specimens fit into one container). Then, the demineralization 
solution (approximately 30 ml per specimen) was added, lid secured and the container 
transferred to an incubator. After approximately 8 h, the specimens were checked for 
bubbles that were moved by shaking the container. After 48 h, the demineralization 
 18 
solution was decanted and the specimens rinsed with deionized water for approximately 1 
min. Specimens were blotted dry with a tissue and stored at approximately 100% relative 
humidity and 4° C until further use. 
Lesion Baseline Microhardness 
Microhardness of the demineralized enamel specimens was determined as 
described above. The average specimen lesion baseline microhardness (VHNlesion) was 
calculated. Only specimens with 25 ≤ VHNlesion ≤ 60 were accepted into the study. 
Specimens were assigned to treatment groups (n = 12) based on a randomization 
procedure that resulted in treatment groups with statistically significantly indifferent 
mean VHNlesion.  
Specimen Mounting 
Once assigned to their treatment groups, specimens were removed from their 
acrylic blocks and mounted onto the inside of a lid of a 12 well microtiter plate as per 
Figure 4. Acrylic blocks (12×12×9 mm) were mounted onto the inside of the lid using 
acrylic glue. Then, specimens were mounted enamel side facing upwards onto the acrylic 
block using sticky wax. 
Fluoride Varnish Application 
The products tested in this study were assigned to groups and labeled as per Table 
5. In addition to the test FVs shown above, two additional experimental groups were 
included, one placebo group (O-; no FV treatment, no toothpaste treatment during pH 
cycling phase) and one positive control group (O+; no FV treatment, toothpaste treatment 
during pH cycling phase). The placebo varnish had the following composition (all w/w): 
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2% shellac; 10% ethyl cellulose; 40% ethyl acetate; 2 % polyvinylpyrrolidone; 2% 
xylitol; 5% NaCl; 39% ethanol and was manufactured in-house especially for this study. 
The protective foil from the individual FV dose was removed and the FV mixed using the 
manufacturer’s application (typically a microbrush) for at least 10 s to homogenize the 
FV, as sedimentation of NaF and phase separation may have occurred during storage. 
Duraphat (group C) was supplied in a tube. For this FV, approximately 0.5 ml was 
squeezed into a small weighing cup and processed as described above. The placebo 
varnish was handled in a similar manner. 
Subsequently, FV was applied to the surface of each specimen using a single 
brush stroke and using the manufacturer’s applicator (typically a microbrush). Any 
unused FV was discarded. 
Saliva Incubation 
Immediately after FV application, the lid containing 12 specimens was placed 
onto the microtiter plate containing 4.0 ml of artificial saliva per well. AS had the same 
composition as previous experiment. Two batches of this solution were prepared, one for 
the FV incubation phase in all specimens and one for the pH cycling phase for all 
specimens. 
The microtiter plate was then placed in an incubator set at 37 °C. Every hour for 6 
h, the lid was removed and rinsed under a stream of running deionized water for exactly 1 
min with all specimens on the lid rinsed in an equal manner. After rinsing, the lid was 
placed onto a new microtiter plate containing 4.0 ml fresh AS per well. 
This procedure was repeated until a total AS exposure time of 6 h has been 
reached. After 6 h, the lid was placed onto a new microtiter plate containing 4.0 ml AS 
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per well which was placed in the incubator for 18 h. After 18 h, the lid was removed and 
rinsed again as described above. All saliva samples were frozen immediately after each 
cycle and retained for analysis of ionic fluoride. 
Then, a soft toothbrush (Oral B P40, Procter & Gamble, USA) was used to brush 
each specimen. A slurry of Crest Cavity Protection (0.243 percent sodium fluoride; 
Procter and Gamble, Mason, Ohio, USA) at a ratio of 1:2 w/w (dentifrice:AS) was 
prepared in a beaker with a magnetic stirrer. The toothbrush was dipped into the slurry 
briefly (approximately 2 s). Each specimen was then brushed under a stream of deionized 
water for 20 s with the specimen being rinsed another 10 s after brushing. This procedure 
was repeated until all specimens on the lid have been brushed. A new toothbrush and 
slurry was used for each lid. After this procedure, the pH cycling phase commenced on 
the same day. 
pH Cycling Phase - Remineralization 
Table 6 highlights the treatment groups per week. As it was anticipated that only a 
total of six treatment groups can be handled per day, the present study was separated into 
three phases which each phase containing a placebo group to allow for comparisons 
between phases. 
The cyclic treatment regimen for each lid containing the specimens consisted of a 
4 h/d acid challenge in the lesion forming solution and one, one-minute treatment period 
with a slurry of aforementioned toothpaste (prepared as described above). One slurry per 
day was prepared and pipetted into each well of the used microtiter plates. The specimens 
were stored in AS throughout the remainder of the pH cycling phase. 
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The pH cycling was performed by placing the lid containing the specimens onto different 
microtiter plates containing 4.0 ml each per well of toothpaste slurry, AS or lesion 
forming solution. The study was conducted at room temperature. After each treatment, 
the specimens were rinsed under running deionized water briefly (approximately 2 s per 
specimen). The regimen was repeated for 5 days. The treatment schedule for this 
experiment is given in Table 7. 
After completion of the pH cycling phase, all specimens were carefully removed 
from the lids and remounted onto an acrylic block to facilitate microhardness and enamel 
fluoride uptake measurements. 
Post Treatment Microhardness 
The average specimen microhardness (VHNpost) was determined again in the same 
manner it was done while obtaining lesion and baseline microhardness. 
Enamel Fluoride Uptake 
The fluoride content of the enamel specimens was determined using the microdrill 
technique. The enamel specimens were mounted perpendicular to the long axis of a micro 
end mill attached to a specially-designed microdrill, and drilled to a depth of 100 µm 
through the entire lesion. The drilling and sample collection were performed in a static-
controlled atmosphere to prevent loss of enamel powder due to charging effects. The 
enamel powder sample was transferred to a diffusion dish and then analyzed for fluoride. 
The diameter of the drill hole was determined using a calibrated microscope interfaced 
with an image analysis system. Indentations for microhardness testing and microdrill 
holes were placed on enamel specimens according to Figure 5. 
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Acid Resistance Test 
To test whether the various FV impart acid resistance to the enamel specimens 
after pH cycling, a second in vitro demineralization treatment was performed and 
following the same protocol as described above but utilizing a demineralization time of 
only 8 h. The average specimen microhardness (VHNart) was determined again as 
described above. 
Artificial Saliva Fluoride Analysis 
The collected, frozen AS samples was thawed. An aliquot is removed and 
analyzed for fluoride by comparison to a similarly prepared standard curve using an ion-
selective electrode (Model 9609BNWP, Orion Research, Boston, MA, USA) and meter. 
Individual as well as cumulative F release data were calculated to determine [F]max 
(highest F concentration found in any collected AS sample over the 24 h period) as well 
as Ftotal (the total amount of F released from FV). 
Statistical Analysis 
One-way analysis of variance (ANOVA) statistical method was used for data 
analysis. An overall significance of (α=0.05) was used. Pair wise comparisons between 
the groups were conducted using Student Newman Keuls test. Pearson correlation 
coefficients were calculated to investigate associations between the study variables.  
Results 
The results for ΔVHN can be found in Table 8, Figures 6 and 7. Nupro was the 
numerically best performing FV with a ΔVHN (post – lesion)= 24.3. However, Nupro did not 
result in significant lesion rehardening when compared to other FV under investigation. 
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Specimens treated with Vella had the least rehardening capability, with a ΔVHN (post – 
lesion)= 11.7 and was not statistically different than placebo.  
For ΔVHN (art – lesion), specimens treated with Sparkle had the highest rehardening 
values following the second acid challenge but were only significantly different from 
those treated with Vella. All other FVs did not statistically affect lesion rehardening 
differently. All FVs performed better than placebo. 
For fluoride release total (Ftotal), MI significantly released the highest amount of 
fluoride over the 24 h incubation period of the experiment (Ftotal=14.97 µg/ml). Enamel 
Pro came second with almost 1/3 less fluoride release than MI. Fluoride release total 
from Enamel Pro was not significantly different than Flor Opal and Nupro. Butler White 
significantly released the least amount of fluoride (Ftotal= 0.50 µg/ml) and was 
approximately 1/30th of that of MI. Results are demonstrated in Table 9 and Figure 8. 
The highest concentration of fluoride at any given time point was for MI ([F]max= 
9.71), however, it was not statically different from Enamel Pro ([F]max= 5.44). Butler 
White exhibited the least concentration ([F]max= 0.17) and was significantly lower than 
all other FV under study (Figure 9).  
Differences between FVs were less prominent for EFU than for Ftotal. PreviDent 
treated lesions exhibited the numerically highest EFU, which was not significantly 
different from most of FVs under investigation apart from Cavity Shield, MI, Flor Opal 
and Butler White (Figure 10). 
There was a significant linear correlation between ΔVHN (post – lesion) vs. EFU (r = 
0.69; p = 0.00135); however, there was no linear correlation between ΔVHN (post – lesion) 
vs. Ftotal (r = 0.41; p = 0.917), and between Ftotal vs. EFU (r = 0.23; p = 0.359). 
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CHAPTER THREE: FLUORIDE CONCENTRATION IN SALIVA AND PLAQUE 
FLUID FOLLOWING THE APPLICATION OF THREE COMMERCIALLY 
AVAILABLE FLUORIDE VARNISHES: A CLINICAL STUDY 
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MATERIALS AND METHODS 
This was a blinded (from laboratory analysis), randomized cross-over, three-
period study in healthy children aged six to eleven years that evaluated the concentration 
of salivary fluoride and plaque fluid fluoride following the application of three 
commercially available FVs.  
Prior to subject recruitment, approval was obtained from the Indiana University 
Institutional Review Board (1409221212). Parental informed consent and child assent 
were collected prior to conduction of this study. The study was conducted at Little 
Flower Catholic School, Indianapolis, IN. 
Based on a previous study on adults (Eackle et al., 2004)38, with a sample size of 
16 subjects, the study has a 80% power to detect a difference of 1.5 for log (AUC) 
between any two treatments, assuming two-sided tests each conducted at a 5% 
significance level, the within-subject correlation is 0.5, and the standard deviation is 2.0. 
To account for 10% dropout, the study enrolled 18 subjects.  
Subjects had to meet the following inclusion and exclusion criteria in order to be 
considered to participate in the study:  
Inclusion Criteria 
1. Age and Gender 
Children (boys and girls) must be seven to eleven years old. 
2. General Health 
Subjects must have good general and oral health with no clinically significant 
medical history or oral disease that could interfere with the subjects’ safety or 
study evaluations during the length of study. 
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3. Dental condition 
a) Have a sufficient number of teeth to obtain adequate plaque samples (at least 
16 teeth). 
b) Have no current dental caries activity, oral soft tissue lesions or periodontal 
disease including severe gingivitis or cavitated carious lesions that may 
compromise the health of subjects or study evaluation.  
4. Compliance  
a) Subject should understand and is willing, able and likely to comply with study. 
b) Subject must be able to abstain from eating for one hour prior to test visit and 
for the two hour duration of visit. 
Exclusion Criteria 
1. Allergy/tolerance 
Known or suspected allergy or hypersensitivity to FV or any of their listed 
ingredients. 
2. Fluoride 
Taking fluoride supplements or other fluoride products for medical purposes 
except for fluoride naturally accruing in diet (Phase 2 only). 
3. Antibiotic Use 
Taking any prescription antibiotics for any medical purpose 
4. Personnel 
A member of the subject’s immediate family living in the same household as one 
of the site study staff directly working on the study. 
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Fluoride Varnish Treatments and Washout Toothpaste 
No experimental fluoride varnish was used in this study. Fluoride varnishes 
contained a standard fluoride level of 5% NaF and were supplied in single dose packages. 
FV packages were weighed before and after treatment application in order to calculate 
the amount of varnish applied. The three fluoride varnishes used in this study were (Table 
10):  
1. CavityShield (CS) 5% Sodium Fluoride Varnish (3M ESPE Dental). 
2. Vanish (V) 5% Sodium Fluoride White Varnish with Tri-Calcium Phosphate (3M 
ESPE Dental). 
3.  Enamel Pro (EP) Varnish Clear (Premier Dental). 
Subjects were asked to use fluoride-free toothpaste (Tom’s of Maine Fluoride 
Free Children’s Toothpaste) for a washout period of 2 weeks prior to the administration 
of the first treatment and for the duration of the study. A two-week washout period is 
common in the literature for studies involving FV. A study by 38 reported that baseline 
fluoride values in the second period have returned to values that are very close to baseline 
fluoride in the first period following a washout period of two weeks 
Randomization Procedures 
A unique screening number was used for all subjects screened for study 
participation. In addition, the study statistician created a randomization schedule to 
determine the order of treatment application for each subject (Table 11). Due to the 
uniqueness of each FV (color, flavor, handling properties) the study investigator had the 
capability to discriminate between varnishes and was therefore blinded to sample analysis 
rather than varnish application.  
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Clinical Procedures and Methodologies 
The investigator completed an oral soft and hard tissue (OSHT) examination at a 
screening visit to ensure only subjects eligible are enrolled into the study. At all other 
visits an oral soft tissue (OST) exam only was performed. Subjects were instructed not to 
brush their teeth or perform any oral hygiene on treatments days and on 24 and 48 h 
collection time points.  
Subjects provided baseline (BL) five-minute, non-stimulated saliva sample, 
followed by collection of interproximal/buccal plaque sample from all teeth immediately 
prior to assigned FV treatment. FV treatment was applied on all teeth surfaces including 
buccal occlusal third/lingual/occlusal of posterior teeth and facial incisal third/lingual of 
anterior teeth. The FV treatment was allowed to set then immediately after saliva samples 
were collected at 30, 60,120 min, 24 and 48 h following the treatment.  Approximately 1 
mg of interproximal/buccal plaque was collected immediately after each saliva sample. 
Subjects remained at school throughout treatment visits. The study investigator brushed 
the occlusal surfaces of the child’s teeth with water and a new tooth brush (Oral B 
Indicator Soft, Procter & Gamble, USA) at the end of each visit. A 2 week washout 
period with fluoride-free toothpaste was observed between treatments to allow fluoride to 
reach baseline levels.  
Saliva Collection Procedure 
Unstimulated whole saliva samples was collected at baseline and immediately 
following treatment at 30, 60, 120 min and at 24 and 48 h. Saliva collection was initiated 
by having the subjects swallow all the residual saliva in their mouth, and then let saliva 
pool in their mouths for the five-minute period while their heads are tilted forward. As 
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the subjects felt the need to swallow, they expectorated into a plastic re-sealable 
collection vial. At the end of the five-min collection period all remaining saliva was 
expectorated into the plastic vial.   
Saliva samples were stored for in a freezer at -20°C for later fluoride analysis. 
Plaque Collection Procedure 
Immediately before dental plaque collection, subjects were instructed to swallow 
all remaining saliva and keep their mouth open. Approximately 1 mg of dental plaque 
was collected from the interproximal and buccal surfaces of teeth of all four quadrants. 
Plaque samples were collected using a standardized protocol. Pooled plaque samples 
were collected using a stainless steel periodontal scaler (S. McCall 17/18 or IU 17/18) 
from each interproximal area from buccal aspect and buccal area starting from the upper 
right quadrant to the upper left, lower left and ending in lower right quadrant. The pooled 
plaque sample was transferred into a plastic strip. 
Laboratory Procedures 
Plaque Sample Preparation 
Prior to plaque sample collection, special centrifuge tubes were constructed by 
heat sealing 10 microliter (µl) micropipette tips. They were filled with heavy mineral oil 
(WSM oil). Microcentrifuge tubes containing the plastic strip and plaque sample were 
centrifuged for 10 min at 10,000 rpm (4,000g) at 4°C.39 Partially oil-filled fine glass 
micro pipettes were used to recover small aliquots (approximately 5 nanoliters) from the 
centrifuged tube under a microscope. 
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Plaque Fluid Fluoride Analysis 
The micro analytical method of  (Vogel et. al., 1990) was used to analyze plaque 
fluid samples for fluoride content:40 
1. Samples were placed, under mineral oil, on the surface of a specially constructed 
inverted F electrode. Mineral oil was used to prevent evaporation. 
2. Total ionic strength adjusting solution (TISAB III) was added to the samples in a ratio 
of 9:1.  
3. The tip of a micro-reference electrode was placed in contact with the sample to 
complete the circuit.  
Triplicate analyses were performed on each pooled plaque fluid sample. Plaque 
fluid fluoride was expressed as µg F/g, which was calculated by comparison to a standard 
fluoride curve, constructed the same day of the analysis. 
Saliva Analysis  
The concentration of fluoride was measured in all saliva samples. Each Saliva 
sample was analyzed as whole and centrifuged for fluoride level. A 1.4 ml of each saliva 
sample was centrifuged 10 min at 10,000 rpm (4,000 g) at 7°C. Analysis of saliva was 
conducted using a modification of the hexamethyl-disiloxane (HMDS,) microdiffusion 
method of (Taves, 1968)41 as modified by (Martinez-Mier et al., 2011)42. One ml of 
centrifuged saliva sample was pipetted into plastic Petri dishes (Falcon 15-cm plastic 
Petri dishes), adding enough deionized water to bring final volume in each Petri dish to 
3.0 ml. A 0.05 sodium hydroxide analytical reagent (NaOH, A.R.) 50 microliters (µl) trap 
solution was placed in five drops on the Petri dish lid and after the addition of 1 ml of 
sulfuric acid (H2SO4) saturated with HMDS through a small hole in the lid of the Petri 
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dish, each dish was immediately tightly sealed with petroleum jelly. During overnight 
diffusion, fluoride was released by acid hydrolysis and was trapped in the NaOH. The 
trap was recovered and buffered to pH 5.2 with 25 µl acetic acid (CH3COOH.). The 
recovered solution was adjusted to a final volume of 100 ml with deionized water. 
Analyses were performed in sets of approximately 40 samples. Fluoride was measured 
using a fluoride combination electrode (Model 9609BNWP, Orion Research, Boston, 
MA, USA) and meter. The fluoride content (µg F) of the samples was calculated from a 
standard curve constructed from fluoride standards and microdiffused at the same time as 
the samples. 
The amount of total fluoride in the samples was calculated based on the amount of 
fluoride divided by the volume of the sample and expressed as µg F/ml of sample. 
The amount of fluoride delivered by the varnish to the saliva over the period of the study, 
i.e. the area under the salivary F clearance curve, was calculated via the trapezium 
method. 
Statistical Analysis  
Intra-examiner repeatability and inter-examiner agreement of the fluoride 
measurements were evaluated using intraclass correlation coefficients. AUC was 
calculated using the trapezoidal method. Statistical analysis for AUC was performed 
using a linear mixed-effects model suitable for a crossover design. The model included 
factors for treatment sequence and baseline fluoride level as covariates, treatment and 
period as fixed factors, with subject as random factor. Pair-wise comparisons among the 
three treatments will be made if the treatment main effect is significant, with no multiple 
comparisons adjustment for the individual pair-wise tests. Analyses of the individual 
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collection times were made using similar models, with additional factors for time and the 
treatment-by-time interaction. Correlation coefficients were calculated to evaluate the 
associations among the fluoride measurements and between the fluoride measurements 
and amount of varnish applied. Analyses used the log-transformed data to satisfy the 
model assumptions. All analyses were performed using SAS version 9.4 (SAS Institute 
Inc., Cary, NC). 
Results 
The results include data from 18 subjects as all subjects completed the study. 
During fluoride collection and analysis, notations were made to identify potentially 
problematic values such as any protocol deviation. For example, two subjects were most 
likely exposed to a fluoride source close to saliva sampling at 24 h. Data analyses were 
performed with and without the outlier values and the conclusions were nearly identical. 
Therefore, only the results from the test without the outliers are presented here.  
Intra-examiner repeatability (ICC=0.93) and inter-examiner agreement (ICC=0.96) were 
both acceptable. Table 12 displays the mean and standard deviation of amount of FV 
applied in g. Mean and standard error of concentration of fluoride in whole and 
centrifuged saliva, and plaque fluid are shown in Table 13. The baseline fluoride values 
ranged from 0.02 to 0.03 ppm in centrifuged saliva and from 0.20 to 0.80 ppm in plaque 
fluid. In general, all values returned to baseline or close to baseline levels after 24 h.  
AUC 
Mean concentration of fluoride over time can be found in Figure 11 (whole 
saliva), Figure 12 (centrifuged saliva) and Figure 13 (plaque fluid). EP had significantly 
lower centrifuged saliva fluoride AUC than CS (p=0.0006) and V (p=0.0008) but CS and 
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V had nearly identical values and were not significantly different from each other 
(p=0.86). V had significantly higher plaque fluid fluoride AUC than CS (p=0.0116) and 
EP (p=0.0065) but CS and EP were not significantly different from each other (p=0.27). 
No significant treatment effect was found for whole saliva fluoride AUC (p=0.79).  
Time Points Comparisons 
Comparisons among FVs at specific time points were also investigated. The time-
by-treatment interaction was significant only for centrifuged saliva (p=0.0319) and 
plaque fluid fluoride (p=0.0312). EP had significantly lower centrifuged saliva fluoride 
than CS and V at 30 min (p=0.0002 and p=0.0033, respectively), at 60 min (p<0.0001, 
p<0.0001), and at 120 min (p=0.0050, p=0.0045); EP was not different from CS or V at 
baseline (p=0.64, p=0.57), 24 h (p=0.85, p=0.49), or 48 h (p=0.88, p=0.91). CS and V did 
not have significantly different centrifuged saliva fluoride regardless of time (p=0.89).  
Centrifuged Saliva 
For all FVs under investigation, centrifuged saliva fluoride was significantly 
higher at 30 min than at any other time (p≤0.0001), followed by 60 min (p≤0.0001) and 
120 min (p≤0.0001), with no significant differences among baseline, 24 h, and 48 h 
(p=0.26 for baseline vs. 24 h, p=0.89 for baseline vs. 48 h, p=0.37 for 24 h vs. 48 h).  
Plaque Fluid 
It was found that at 30 min EP had significantly lower plaque fluid fluoride than 
CS (p=0.0449) and V (p=0.0006) but CS and V were not different from each other 
(p=0.16). At 60 min, EP (p=0.0045) and CS (p=0.0353) had significantly lower plaque 
fluid fluoride than V but EP and CS were not different from each other (p=0.48). No 
treatment effect was found at baseline (p=0.88), 120 min (p=0.11), 24 h (p=0.55), or 48 h 
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(p=0.40). For CS, plaque fluid fluoride was significantly higher at 30 min than at any 
other time (p<0.01), followed by 60 and 120 min (p<0.0001), with no significant 
differences among baseline, 24, and 48 h (p=0.19 for baseline vs. 24 h, p=0.59 for 
baseline vs. 48 h, p=0.41 for 24 vs. 48 h) or between 60 and 120 min (p=0.70). For EP, 
plaque fluid fluoride was significantly higher for 30, 60, and 120 min compared to 
baseline, 24, and 48 h (p<0.0001), while there were no differences among baseline, 24, 
and 48 h (p=0.18 for baseline vs. 24 h, p=0.65 for baseline vs. 48 h, p=0.33 for 24 vs. 48 
h) or among 30, 60, and 120 min (p=0.26 for 30 vs. 60 min, p=0.78 for 30 vs. 120 min, 
p=0.29 for 60 vs 120 min). For V, plaque fluid fluoride was significantly higher for 30, 
60, and 120 min compared to baseline, 24, and 48 h (p<0.0001), and higher for 30 than 
120 min (p=0.0030), while there were no differences among baseline, 24, and 48 h 
(p=0.44 for baseline vs. 24 h, p=0.82 for baseline vs. 48 h, p=0.24 for 24 vs 48 h) and no 
differences between 60 and 30 min (p=0.11) or 120 min (p=0.21). 
Correlations between Study Variables 
Whole and centrifuged saliva fluoride AUC were highly correlated for CS 
(r=0.84), EP (r=0.82), and V (r=0.88). Plaque fluid fluoride AUC was moderately 
correlated with whole saliva fluoride AUC (r=0.44, p=0.09) and centrifuged saliva 
fluoride AUC (r=0.44, p=0.08) for CS but not for the other two treatments. Many of the 
individual time points had moderate to high correlations between whole and centrifuged 
saliva fluoride, but plaque fluid fluoride was rarely associated with whole or centrifuged 
saliva fluoride at the individual time points. 
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DISCUSSION 
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The clinical efficacy of fluoride varnishes in preventing dental caries has been 
well documented in the literature.12, 43 Fluoride varnishes last for a limited time in the oral 
cavity and are quickly removed by the action of mastication and oral hygiene practices. 
Therefore, varnishes are designed to release their active ingredients in a relatively short 
time that has been estimated to be up to 24 h.28, 44 Since the introduction of the first 
fluoride varnishes, researchers have been striving to improve FV by testing new 
formulations that aim to better deliver fluoride in varnishes.45, 46 However, fundamental 
research on how different formulations affect fluoride release into saliva, uptake by teeth, 
and changes in microhardness of enamel after FV application is needed to establish a 
baseline for product comparisons. 
Our first experiment aimed to evaluate the effect of five commercially available 
FV products on caries lesions by investigating the amount of fluoride released from each 
varnish into AS; the amount of fluoride delivered to early enamel carious lesions; and the 
extent of surface rehardening of these lesions as a result of a FV treatment. To the 
authors’ knowledge, this is one of the first in vitro studies to employ three response 
variables (F release, EFU and VHN) and to study correlations among them. The chosen 
experimental design was based on previous studies 7, 12, 28, 47 while taking into account 
findings from preliminary in-house investigations (unpublished data).  
Our first study findings indicate that varnishes containing amorphous calcium 
phosphate (ACP) forming salts and casein-phosphopeptide-amorphous calcium 
phosphate (CPP-ACP) demonstrated significantly higher ability to reharden early carious 
lesions than the other tested FV. This may be explained by the higher amounts of 
available calcium and phosphate ions from varnishes containing ACP forming salts. 
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Recently, it was shown that ACP forming varnish formulations delivered more fluoride 
than formulations containing tri-calcium phosphate (TCP) to both sound and 
demineralized enamel. This was likely due to the non-crystalline structure of ACP that 
makes it more soluble and reactive compared to TCP that is an insoluble crystalline form 
of calcium phosphate.44 
The results of our first study demonstrate a wide variation in total fluoride release 
over six hours from the five varnishes under investigation. This wide variation in fluoride 
release amount and characteristics is difficult to explain since manufacturers are not 
required to provide exact formulation details. However, this variation may be due to the 
differences in additives or type of resin carriers (natural vs. synthetic) used. It has been 
postulated that fluoride ion diffusion is slower in varnishes with a natural resin base; 
however, this was not observed in this study.47, 48 For example, Flor-Opal has a natural 
resin base (rosin) and released more fluoride than Vanish that has a synthetic resin base.  
The highest release from all varnishes was within the first 15 min to 1 h of 
application and is similar to another study.47 In our first study, it was found that the 
highest total fluoride release over the period of six hours was from a varnish containing 
CPP-ACP as an additional active ingredient, while the least amount of release was from a 
varnish with functionalized tri-calcium phosphate. These findings are in agreement with 
another study and are consistent with the high water solubility and bioavailable nature of 
CPP-ACP contained within these varnishes.49 
The present findings for EFU for our first experiment are in contrast to our 
expectations for some of the evaluated FVs. For example, MI exhibited the greatest level 
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of total fluoride release and a high level of rehardening value but a low level of EFU. 
This FV contains CPP-ACP and was found to release relatively high amounts of 
inorganic phosphate.28 High levels of inorganic phosphate have been found to negatively 
impact the formation of CaF2 thereby reducing the amount of bioavailable fluoride ion 
that is required for remineralization, and this may be an explanation for the lower level of 
EFU for MI varnish. 
In our first experiment, we were unable to observe correlations between the 
outcome variables. This is in agreement with a prior study in our laboratory which 
employed a similar range of FVs.10 For example, a FV that demonstrated a high fluoride 
release into saliva did not necessarily result in a high EFU value or enhanced 
remineralization. It is important to note that while there are similarities in the 
experimental models between studies, they were inherently different. Most importantly, 
the present study was concerned with FV effects on lesions after a pH cycling phase to 
mimic the short term effect of FV on lesions whereas our previous study was solely 
concerned with the immediate effect of FV on lesions. The observed differences in FV 
performance but consistencies in lack of correlation between variables highlight some of 
the shortcomings of laboratory research on FV. In the absence of a clinically validated in 
vitro model to determine the efficacy of FV, results from the present and previous 
laboratory studies need to be seen with caution. 
In the second in vitro study, we aimed to investigate the efficacy of fifteen 
commercially available FVs using the same outcome variables in our first study. While 
the two studies investigated the effect of FVs on caries lesions, the study models were 
fundamentally different. The wide variation in performance of FV in our first experiment 
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prompted the design of our second in vitro study. We aspired to have a better 
understating of how different formulations affect efficacy of FVs. Therefore, in our 
second experiment we aimed to investigate a larger variety of FVs in an attempt to have a 
range of products that represent different formulations. Also, in the second study FVs 
were left on the specimens for a prolonged period of 24 h vs. the 6 hr period of the first 
study to better simulate the clinical situation. 
The second in vitro experiment’s results for ΔVHN (post – lesion) and for ΔVHN (art – 
lesion) were unanticipated. As there are numerical differences in lesion rehardening values 
from different FVs, most of the FVs did not statistically differ from each other. As 
previously mentioned, it is hard to thoroughly interpret the results due to lack of detailed 
information on different FV formulations. However, there seems to be a superior effect 
on lesion rehardening when calcium and phosphate containing ingredients are added to 
the formulation. This is in agreement with our first in vitro study and with data available 
in the literature, and is explained in detail in the first segment of the discussion. It is 
important to note that the enhanced rehardening effect from calcium and phosphate 
containing ingredients did not withstand the second acid challenge. This is in contrast to a 
recent systematic review that suggested a possible long term effect (> 3 months) of CPP-
ACP complexes on early caries lesions, however the results cannot be extrapolated as the 
review investigated CPP-ACP alone due to insufficient evidence on the complex’s 
synergistic effect with fluoride.50 Another noteworthy finding is that lesions treated with 
Vanish, a FV containing functionalized TCP (fTCP), had a higher ΔVHN (post – lesion) than 
those treated with FVs containing ACP and CPP-ACP. This may be due to the protective 
effect of functionalization of the TCP molecule that prevents premature interaction 
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between calcium and fluoride and aids in remineralization in a manner similar to that of 
fluoride.51  
The fluoride release data in our second in vitro experiment is in agreement with 
our previously mentioned in house experiment and (Cochrane et al.,2014).28 Calcium 
containing FVs, with the exception of fTCP containing varnishes, were able to release 
significantly higher levels of fluoride into saliva. This suggests a synergistic effect of 
adding casein complexes to FVs on fluoride release and may be explained by the 
bioavailable nature of ACP and CPP-ACP compared to the less soluble fTCP.44, 51 
EFU data from our second study extends our results from our aforementioned first 
in vitro investigation. Once again, a CPP-ACP containing varnish delivered less fluoride 
into caries lesions. Our explanation is noted earlier in the discussion section. Vanish, a 
FV containing fTCP, delivered more fluoride into lesions compared to CPP-ACP and 
ACP containing FV in spite of its low fluoride release into saliva. This is in agreement 
with a study that compared EFU from two varnishes, one containing fTCP and the other 
containing CPP-ACP.44 Also, another study compared EFU with and without tTCP. It 
was found that lesions exposed to fluoride in conjunction with fTCP had significantly 
higher fluoride uptake than those exposed to fluoride alone and the effect of fTCP was 
dose dependent. The mechanism of action of fTCP on enhancing lesion uptake of fluoride 
is not fully understood but may be attributed to the ability of fTCP to promote fluoride-
based nucleation.51 
Contrary to our findings in our first in vitro study, we were able to demonstrate a 
significant linear correlation between ΔVHN (post – lesion) and EFU. To our best knowledge, 
this is the first time a correlation was established between ΔVHN and EFU in FV 
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research. More work should be completed before using one of the variables as a 
predictive factor for the other. 
In our clinical study we aimed to compare the differences in AUC of fluoride 
concentrations in saliva and plaque fluid following the application of three commercially 
available fluoride varnishes. All FVs had a common fluoride source of 5% NaF and the 
study did not experience any dropouts.  
It is important to note that the literature is very scarce when it comes to clinical 
studies evaluating the pharmacokinetics of fluoride release into saliva and plaque post FV 
applications. Also, the available study models vary significantly making comparisons a 
difficult task. With that being said, a conscious effort was made to critically analyze 
related studies while designing our model. Also, we believe that we are the first to 
analyze both saliva and plaque fluid simultaneously in an attempt to find a correlation 
between fluoride concentrations in both release media. 
The amount of CS applied was less than that of the other FVs. This was possibly 
due to the high viscosity of the varnish that resulted in less varnish being picked up by 
the application brush. However, when correlations were made, it was found that fluoride 
AUC measurements for centrifuged saliva and plaque fluid were not associated with the 
amount of varnish applied. 
The fluoride release from FVs tested in our clinical study demonstrated different 
concentrations but similar release patterns for the collection periods of the study. All FVs 
resulted in peak fluoride levels in saliva and plaque fluid at 30 min post application 
followed by a steady decline. Most salivary and plaque fluid fluoride levels returned to 
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baseline by 24 h. The release pattern is very typical for FV release kinetics and compares 
well with findings from (Twetman et al., 1999) and (Eakle et al., 2004), where salivary 
fluoride levels peaked at 1 hr and 15 min after FV application respectively.32, 38 
The significantly lower levels of AUC from EP in both centrifuged saliva and 
plaque fluid maybe related to our subjective finding of its lower viscosity compared to 
the other FVs under investigation. This extends the findings of (Downey, 2013) were a 
relatively similar model was used.52 We found that EP adhered less to teeth in the process 
of application and is more likely to seep away from the application zone and therefore 
maybe swallowed before it reaches its fluoride release potential. This finding is 
inconsistent with EP’s behavior in our in vitro investigations and with the literature as EP 
consistently released more fluoride in vitro conditions.7, 10, 28 This is perhaps due to the 
closed system in an in vitro model, where saliva has no pathway to exit the confined area 
of release. And this may lead us to conclude that EP has the capability of high fluoride 
release, though it is not sustained in the oral cavity under in vivo conditions. Since the 
levels of fluoride in saliva and plaque fluid are indicative of the amount of fluoride that is 
bioavailable to interact with tooth structure and is of critical importance in producing an 
anti-caries effect, we can cautiously state that EP is less effective as a FV than the other 
tested products, however more research is required before clinical recommendations can 
be made.30, 31, 53 
Another noteworthy finding is the significantly higher plaque fluid fluoride AUC 
in subjects treated with V. This varnish contains fTCP, a calcium-phosphate ingredient 
that is well known to enhance fluoride activity by promoting its nucleation.51 The calcium 
added to the formulation possibly acts as a scavenger for fluoride and thereby aids in 
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increasing the amount of fluoride reservoirs in plaque fluid.54, 55 The bioavailability of 
fluoride in both saliva and plaque is essential in governing the caries process, however 
salivary fluoride levels quickly fall below levels of fluoride in plaque fluid thus making 
fluoride ions in plaque the prime factor in the demineralization/remineralization 
process.30, 56 It is important to note that plaque consists of multiple phases, namely plaque 
solid and plaque fluid. Our analysis focused on the latter and therefore the results and 
interpretations made here are based on our investigation of the plaque fluid phase only.  
Based on our recent findings and previous knowledge of factors predicting efficacy of 
topical fluoride applications and within the limitations of our study, we can conclude that 
V is likely to have more anti caries potential compared to CS and EP, however, future 
evaluation is needed to support this finding.  
The concentration of fluoride in saliva was rarely associated with plaque fluid 
fluoride at the examined time points. This is in disagreement with Vogel et al. that found 
a strong linear correlation between levels of fluoride in saliva and plaque fluid at 30 and 
60 min after administration of NaF rinse.57 The high correlation may be attributed to the 
liquid nature of the rinse in contrast to the viscous formulation of FVs in our study that 
allows a faster dissociation of fluoride from saliva to plaque from the rinse. 
One or all of the investigated variables, in our in vitro and in vivo studies, may 
predict the efficacy of FVs. However, it is impossible to foresee at this point the best 
predictive variable for clinical performance. There is a need to develop and validate 
clinical and laboratory models that will help us better understand the mode of action of 
FVs and predict clinical efficacy. 
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CONCLUSIONS 
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1. Our in vitro investigations revealed that FVs differed in their release characteristics 
rehardening capability, and ability to deliver fluoride to demineralized lesions.  
2. Our in vitro studies showed significantly higher fluoride release in AS from FVs with 
an additional calcium phosphate source. 
3. Our laboratory and clinical investigations demonstrated that fluoride release profiles 
were somewhat similar between FVs as all showed a gradual decrease in released 
fluoride over time.  4. In vitro models are not suitable for predicting fluoride release behavior and   therefore 
may not be a good choice for studying the kinetics of fluoride release from FVs.. 	  5. 	  The observed differences in vitro and in vivo may be attributed to different 
compositions and the presence of other active ingredients besides fluoride in the FVs 
tested.	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TABLES  
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Table 1. Study test products. 
Fluoride 
Varnish 
Manufacturer 
Fluoride 
Source and 
Concentration 
Carrier 
Other Active 
Ingredient 
Enamel Pro Premier Dental 5% NaF Rosin 
Amorphous 
calcium 
phosphate 
(ACP), Xylitol 
Flor-Opal Ultradent 5% NaF 
Hydrogenated 
Rosin 
Xylitol 
MI Varnish GC America 5% NaF 
Hydrogenated 
Rosin, Polyvinyl 
acetate 
Casein 
phosphopeptide-
ACP (CPP-
ACP, Recaldent) 
PreviDent 
Colgate-
Palmolive 
5% NaF Synthetic resin Xylitol 
Vanish 3M ESPE 5% NaF 
Pentaerythritol 
glycerol ester of 
colophony resin 
Functionalized 
tri-calcium 
phosphate 
(fTCP), Xylitol 
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Table 2. Daily pH cycling treatment schedule. 
Time Treatment 
8:00-8:01 a.m. Toothpaste treatment 
8:01-10:00 a.m. Artificial saliva 
10:00 a.m.-2:00 p.m. Acid challenge 
2:00-4:00 p.m. Artificial saliva 
4:00-4:01 p.m. Toothpaste treatment* 
4:01 p.m.-8:00 a.m. Artificial saliva 
 
*On the last day, this treatment was not given; the test ended with the AS treatment at 4 
pm. 
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Table 3. Mean ΔVHN and SD. 
Fluoride Varnish n Mean ΔVHN (SD) 
Enamel Pro 15 32.3 (5.8)a 
Flor-Opal 18 20.4 (7.4)bc 
MI Varnish 18 25.9 (12.5)b 
PreviDent 16 24.7 (6.2)bc 
Vanish 16 18.9 (11.3)c 
 
*Superscript letters represent significant differences of ΔVHN means.  
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Table 4. Cumulative fluoride release and peak fluoride concentration (n=1). 
Fluoride Varnish 
Cumulative Fluoride Release 
[µg/ml] 
Peak Fluoride 
Concentration [µg/ml] 
Enamel Pro 216.7 76.9 
Flor-Opal 153.0 56.7 
MI Varnish 303.0 72.9 
PreviDent 84.3 14.6 
Vanish 27.6 4.2 
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Table 5. Study test products. 
Group Product Manufacturer 
A CavityShield 5% Varnish 3M ESPE 
B Vanish 5% NaF Varnish w/ TCP 3M ESPE 
C Colgate Duraphat Varnish Colgate Oral Pharmaceuticals 
D Colgate Prevident Varnish Colgate Oral Pharmaceuticals 
E Sparkle V Varnish Crosstex International 
F Nupro 5% Fluoride Varnish Dentsply Professional Division 
G Kolorz Clearshield Varnish DMG America 
H MI Varnish GC America 
I Duraflor Halo 5% Sodium Fluoride 
Varnish 
Medicom 
J Enamel Pro Varnish Clear Premier Dental 
K Vella Fluoride Varnish Preventive Technologies 
L Butler White Fluoride Varnish Sunstar Americas, Inc. 
M Flor-Opal Varnish White Fluoride Varnish Ultradent 
N Waterpik UltraThin Varnish Waterpik Technologies Inc. 
O Placebo Varnish (Manufactured in house) 
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Table 6. Treatment groups for pH cycling phase 
 
 
 
 
 
 
Week FV treatment groups 
1 A, B, C, D, E, O- 
2 F, G, H, I, O-, O+ 
3 J, K, L, M, N, O- 
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Table 7. Daily pH cycling treatment schedule. 
Time Treatment 
10:00-10:01 a.m. Toothpaste treatment* 
10:01-12:00 a.m. Artificial saliva 
12:01 a.m.-4:00 p.m. Acid challenge 
4:01-10:00 a.m. Artificial saliva 
 
*Specimens in placebo group did not receive this treatment and were stored in deionized 
water instead. 
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Table 8. ΔVHN (post – lesion) Mean and SD (n=12). 
 
Fluoride Varnish ΔVHN (post – lesion) Mean (SD) Statistical Significance* 
Butler White 42.1 (9.2) A,B,C 
CavityShield 48.9 (10.8) A,B 
Duraflor Halo 39.4 (8.9) A,B 
Duraphat 46.0 (9.4) A,B 
Enamel Pro 46.0 (10.0) A,D 
Flor Opal 41.0 (7.4) A,B,C 
Kolorz 44.6 (9.3) A,B 
MI 42.2 (7.6) A,B 
Vella 39.6 (6.8) A,B,C 
Nupro 49.6 (10.8) A 
PreviDent 43.3 (9.8) A,B,C 
Sparkle 51.8 (16.6) A,D 
Vanish 49.2 (7.6) A,D 
Waterpik 49.8 (11.4) A,B,C 
O-a 29.3 (9.5) C,D 
O-b 28.3 (7.0) B 
O-c 28.3 (7.0) B,D 
O+ 37.8 (8.7) A,B,C 
 
*Different letters highlight statistically significant differences. 
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Table 9. Cumulative fluoride release and peak fluoride concentration (n=12). 
 
Fluoride Varnish 
Cumulative Fluoride 
Release [µg/ml] Mean 
(SD) 
Peak Fluoride 
Concentration [µg/ml] 
Mean (SD) 
Butler White 0.50 (0.15) 0.17 (0.09) 
CavityShield 1.97 (0.14) 1.28 (0.11) 
Duraflor Halo 1.82 (0.54) 0.70 (0.22) 
Duraphat 2.64 (0.53) 0.97 (0.12) 
Enamel Pro 9.20 (1.71) 5.44 (1.05) 
Flor Opal 8.20 (1.91) 4.37 (0.85) 
Kolorz 2.91 (0.46) 1.00 (0.11) 
MI 14.97 (2.38) 9.71 (1.40) 
Vella  4.91 (2.02) 2.57 (2.17) 
Nupro 6.96 (1.26) 1.69 (0.43) 
PreviDent 2.82 (0.59) 0.98 (0.09) 
Sparkle 2.19 (0.47) 0.95 (0.15) 
Vanish 2.63 (0.53) 1.28 (0.09) 
Waterpik 3.07 (0.81) 0.93 (0.30) 
O-a 2.15 (0.56) 1.20 (0.30) 
O-b 0.85 (0.17) 0.71 (0.16) 
O-c 0.81 (0.55) 0.55 (0.51) 
O+ 0.49 (0.16) 0.37 (0.16) 
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Table 10. Clinical study test products. 
 
Fluoride 
Varnish 
Manufacturer 
Fluoride 
Source and 
Concentration 
Carrier 
Other Active 
Ingredient 
Enamel Pro Premier Dental 5% NaF Rosin 
Amorphous 
calcium 
phosphate 
(ACP), Xylitol 
CavityShield 3M ESPE 5% NaF 
Colophony, 
Polyamide Resin 
N/A 
Vanish 3M ESPE 5% NaF 
Pentaerythritol 
glycerol ester of 
colophony resin 
Functionalized 
tri-calcium 
phosphate 
(fTCP), Xylitol 
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Table 11.Treatment randomization schedule. 
 
 
 
 
 
 
 
 
 
 
 
Randomization number Period 1 Period 2 Period 3 
1 CavityShield Vanish Enamel Pro 
2 Enamel Pro Vanish CavityShield 
3 Vanish Enamel Pro CavityShield 
4 Vanish CavityShield Enamel Pro 
5 CavityShield Enamel Pro Vanish 
6 Enamel Pro CavityShield Vanish 
7 Vanish CavityShield Enamel Pro 
8 Enamel Pro Vanish CavityShield 
9 CavityShield Enamel Pro Vanish 
10 CavityShield Vanish Enamel Pro 
11 Enamel Pro CavityShield Vanish 
12 Vanish Enamel Pro CavityShield 
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Table 12. Mean amount of treatment applied in g and SD 
Treatment N Mean (SD) 
CS 18 0.13 (0.04)a 
EP 18 0.24 (0.06)a 
V 18 0.27 (0.11)a 
 
*Different letters highlight statistically significant differences 
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Table 13. Mean concentration (SE) of fluoride in whole saliva, centrifuged saliva and plaque fluid. 
 
  CS EP V 
Measurement Time N Mean (SE) 
Mean (SE) 
log-transf. N Mean (SE) 
Mean (SE) 
log-transf. N Mean (SE) 
Mean (SE) 
log-transf. 
Whole Saliva F AUC 17 83 (14) 4.22 (0.16) 16 76 (11) 4.16 (0.16) 16 66 (7) 4.10 (0.12) 
 BL 18 0.07 (0.03) -3.58 (0.35) 17 0.05 (0.02) -3.77 (0.32) 17 0.06 (0.02) -3.33 (0.27) 
 30min 17 20.86 (3.46) 2.57 (0.37) 18 14.47 (2.52) 2.43 (0.17) 18 18.12 (2.89) 2.57 (0.23) 
 60min 17 8.08 (1.02) 1.72 (0.33) 18 7.70 (1.22) 1.85 (0.15) 18 8.87 (1.60) 1.91 (0.19) 
 120min 18 5.57 (1.05) 1.49 (0.16) 16 5.23 (0.84) 1.45 (0.17) 16 4.34 (0.44) 1.38 (0.12) 
 24hr 17 0.05 (0.01) -3.32 (0.21) 17 0.06 (0.01) -3.08 (0.26) 15 0.06 (0.02) -3.32 (0.32) 
 48hr 16 0.07 (0.04) -3.70 (0.31) 17 0.08 (0.04) -3.18 (0.24) 15 0.05 (0.01) -3.37 (0.25) 
Centrifuged 
Saliva F AUC 17 51 (7) 3.75 (0.17) 18 23 (3) 2.96 (0.15) 18 51 (8) 3.71 (0.18) 
 BL 18 0.03 (0.01) -4.09 (0.25) 17 0.02 (0.00) -4.23 (0.19) 18 0.03 (0.01) -4.05 (0.22) 
 30min 18 18.77 (2.53) 2.75 (0.16) 18 6.27 (1.09) 1.38 (0.37) 18 14.82 (2.31) 2.44 (0.20) 
 60min 18 6.38 (0.77) 1.66 (0.17) 18 2.80 (0.47) 0.79 (0.18) 18 7.02 (1.24) 1.68 (0.19) 
 120min 17 3.15 (0.48) 0.84 (0.23) 18 1.49 (0.24) -0.01 (0.29) 18 3.28 (0.53) 0.93 (0.19) 
 24hr 18 0.02 (0.00) -3.98 (0.14) 18 0.02 (0.00) -4.01 (0.17) 18 0.03 (0.01) -3.87 (0.20) 
 48hr 17 0.07 (0.06) -4.12 (0.31) 18 0.04 (0.02) -4.07 (0.26) 18 0.02 (0.01) -4.10 (0.19) 
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Plaque F AUC 17 1237 (440) 6.16 (0.40) 17 525 (82) 6.05 (0.18) 18 1916 (468) 7.14 (0.22) 
 BL 17 0.2 (0.0) -1.83 (0.10) 18 0.8 (0.6) -1.68 (0.28) 17 0.5 (0.4) -1.79 (0.26) 
 30min 17 187.2 (41.9) 4.65 (0.34) 17 58.1 (9.2) 3.40 (0.45) 18 685.9 (205.7) 5.49 (0.49) 
 60min 17 127.0 (39.5) 3.32 (0.59) 18 43.2 (9.0) 2.85 (0.48) 18 171.4 (38.0) 4.69 (0.25) 
 120min 17 90.4 (35.0) 3.15 (0.52) 18 37.5 (6.4) 3.29 (0.24) 18 124.9 (33.5) 4.16 (0.31) 
 24hr 16 0.3 (0.1) -1.45 (0.18) 18 0.5 (0.1) -1.32 (0.23) 18 0.3 (0.1) -1.58 (0.14) 
 48hr 16 0.2 (0.0) -1.69 (0.11) 18 0.4 (0.2) -1.55 (0.23) 18 0.2 (0.0) -1.86 (0.13) 
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FIGURES 
 62 
 
Figure 1. Mean change in surface microhardness (ΔVHN) as a function of fluoride 
varnish treatment. Significant differences between varnishes are highlighted by different 
letters. Error bars denote standard deviations.  
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Figure 2. Fluoride release (log10 scale for better clarity) from fluoride varnishes into 
saliva as a function of time (n=1). 
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Figure 3. Enamel fluoride uptake (EFU; consecutive etches and combined data) as a 
function of fluoride varnish treatment. EFU was normalized per ml of acid etch solution. 
The dashed, horizontal line represents the lowest fluoride concentration of the calibration 
curve. Values lower than 0.01 µg/ml were calculated based on extrapolation of the 
calibration curve 
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Figure 4. Illustration of 12 well microtiter plate lid with mounted acrylic blocks and 
specimens. 
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Figure 5. Enamel specimen (5 × 5 mm) with microhardness indentations and microdrill 
holes. 
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Figure 6. Mean change in surface microhardness (ΔVHN(post – lesion)) as a function of 
fluoride varnish treatment. Significant differences between varnishes are highlighted by 
different letters. Error bars denote standard deviations.
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Figure 7. Mean change in surface microhardness (ΔVHN(art – lesion)) as a function of 
fluoride varnish treatment. Significant differences between varnishes are highlighted by 
different letters. Error bars denote standard deviations.
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Figure 8. Ftotal from fluoride varnishes into saliva as a function of time. Different letters 
highlight significant differences between varnishes. Error bars denote standard 
deviations.
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Figure 9. [F]max the highest concentration of fluoride at any given time point as a 
function of fluoride treatment. Different letters highlight significant differences between 
varnishes. Error bars denote standard deviations.
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Figure 10. Enamel fluoride uptake (EFU) as a function of fluoride varnish treatment. 
Different letters highlight significant differences between varnishes. Error bars denote 
standard deviations 
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Figure 11. Mean concentration of fluoride release into whole saliva from fluoride 
varnishes as a function of time (log10 scale for better clarity).  
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Figure 12. Mean concentration of fluoride release into centrifuged saliva from fluoride 
varnishes as a function of time (log10 scale for better clarity).  
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Figure 13. Mean concentration of fluoride release into plaque fluid from fluoride 
varnishes as a function of time (log10 scale for better clarity). 
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